<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700124</url>
  </required_header>
  <id_info>
    <org_study_id>3475-B15</org_study_id>
    <secondary_id>MK-3475-B15</secondary_id>
    <secondary_id>KEYNOTE-B15</secondary_id>
    <secondary_id>EV-304</secondary_id>
    <secondary_id>2020-003106-31</secondary_id>
    <secondary_id>jRCT2041210011</secondary_id>
    <nct_id>NCT04700124</nct_id>
  </id_info>
  <brief_title>Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)</brief_title>
  <acronym>KEYNOTE-B15</acronym>
  <official_title>A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the antitumor efficacy and safety of perioperative&#xD;
      enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node&#xD;
      dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy&#xD;
      [gemcitabine plus cisplatin] and RC + PLND) for participants with MIBC who are&#xD;
      cisplatin-eligible. The dual primary hypotheses are preoperative EV + pembrolizumab and RC +&#xD;
      PLND (Arm A) will achieve superior pathologic complete response (pCR) rate and perioperative&#xD;
      EV and pembrolizumab and RC + PLND (Arm A) will achieve superior event free survival (EFS)&#xD;
      compared with neoadjuvant gemcitabine + cisplatin and RC + PLND (Arm B).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Anticipated">June 23, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 23, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response (pCR) Rate</measure>
    <time_frame>Up to approximately 42 months</time_frame>
    <description>pCR rate is defined as defined as the proportion of participants having pCR. pCR is defined as absence of viable tumor (pT0N0) in examined tissue from radical cystectomy (RC) + pelvic lymph node dissection (PLND), as assessed by blinded central pathologic review.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>EFS is defined as the time from randomization to the first occurrence of following events: radiographic disease progression precluding RC + PLND, failure to undergo surgery in participants with residual disease, gross residual disease left behind at time of surgery, local or distant recurrence based on blinded independent central review (BICR) or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>From approximately 12 months to up to approximately 5 years</time_frame>
    <description>DFS is defined as the time from postsurgery baseline scan until the first occurrence of either local/distant recurrence as assessed by BICR imaging and/or biopsy or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic Downstaging (pDS) Rate</measure>
    <time_frame>Up to approximately 42 months</time_frame>
    <description>pDS is defined as participants with &lt;pT2 (includes pT0, pTis, pTa, and pT1) and N0 in examined tissue from RC plus PLND, based on central pathologic review.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced An Adverse Event (AE) (Arm A only)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Treatment Due to An AE (Arm A only)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score</measure>
    <time_frame>Baseline, Up to approximately 5 years</time_frame>
    <description>The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer participants. Participant responses to questions 29 (&quot;How would you rate your overall health during the past week?&quot;) and 30 (&quot;How would you rate your overall quality of life during the past week?&quot;) are scored on a 7-point scale (1= Very poor to 7=Excellent). A higher score indicates a better overall health/quality of life status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined scores will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in EORTC QLQ-C30 Physical Functioning Scale</measure>
    <time_frame>Baseline, Up to approximately 5 years</time_frame>
    <description>The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=not at all to 4=very much). A higher score indicates a better quality of life. The change from baseline in physical function (EORTC QLQ-C30 Items 1-5) score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urinary, Bowel and Sexual Domains per Bladder Cancer Index (BCI)</measure>
    <time_frame>Baseline, Up to approximately 5 years</time_frame>
    <description>The BCI is a 36-item validated, condition-specific health questionnaire to assess the quality of life among participants with bladder cancer. The BCI contains 3 domains: urinary (14 items), bowel (10 items), and sexual (12 items) with function (Likert response scale: 0 [Never] - 4 [Always]) and bother (Likert response scale: 0 [No problem] - 4 [Big problem]) subdomains. The domain and subdomain scores are standardized to a 0 to 100 point scale where higher scores correspond better functioning and health-related qualify of life. The change from baseline in the combined scores of the urinary, bowel, and sexual domains of the BCI will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in EuroQoL-5 Dimensions, 5-level Questionnaire (EQ-5D-5L) Visual Analogue Score (VAS)</measure>
    <time_frame>Baseline, Up to approximately 5 years</time_frame>
    <description>The EQ-5D-5L VAS records the respondent's self-rated health on a 10 centimeter (cm) vertical, visual analogue scale. It is rated by the respondent on a scale 0 to 100, with 0 being &quot;the worst health you can imagine&quot; and 100 being &quot;the best health you can imagine&quot;. The change from baseline in EQ-5D-5L VAS will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration (TTD) in the EORTC-QLQ-C30 Global Health Status/Quality of Life (Items 29 and 30)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer participants. Participant responses to questions 29 (&quot;How would you rate your overall health during the past week?&quot;) and 30 (&quot;How would you rate your overall quality of life during the past week?&quot;) are scored on a 7-point scale (1= Very poor to 7=Excellent). A higher score indicates a better overall health/quality of life status. TTD is defined as time from baseline to first onset of EORTC-QLQ-C30 Global Health Status/Quality of Life (Items 29 &amp; 30) deterioration based on established minimal important differences (MIDs) threshold. Deterioration in the global health status/quality of life of the EORTC QLQ-C30 is defined as a 10 points or greater worsening from baseline, with or without subsequent confirmation, under a right-censoring rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTD in the Physical Functioning Scale per EORTC QLQ-C30</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). A higher score indicates a better quality of life. The TTD is defined as the time from baseline to first onset of the physical functioning scale per EORTC QLQ-C30 deterioration based on established MIDs threshold. Deterioration is defined as a 10 points or greater worsening from baseline with or without subsequent confirmation, under a right-censoring rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTD in the Urinary, Bowel and Sexual Domains per BCI</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>The 36-item BCI contains 3 domains: urinary (14 items), bowel (10 items), and sexual (12 items) with function (Likert response scale: 0 [Never] - 4 [Always]) and bother (Likert response scale: 0 [No problem] - 4 [Big problem]) subdomains. The domain and subdomain scores are standardized to a 0 to 100 point scale where higher scores correspond to better functioning and health-related quality of life. TTD is defined as time from baseline to first onset of urinary, bowel and sexual domains per BCI deterioration based on established MIDs threshold. Deterioration is defined based on the published median MIDs as a 6, 7, and 7 points or greater worsening from baseline for urinary, bowel, and sexual domains, respectively, with or without subsequent confirmation, under a right-censoring rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTD in the EQ-5D-5L VAS</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>The EQ-5D-5L VAS records the respondent's self-rated health on a 10 cm vertical, visual analogue scale. It is rated by the respondent on a scale 0 to 100, with 0 being &quot;the worst health you can imagine&quot; and 100 being &quot;the best health you can imagine&quot;. TTD is defined as the time from baseline to first onset of EQ-5D-5L VAS deterioration based on established MIDs threshold. Deterioration in score is defined in as a 7 points or greater worsening from baseline with or without subsequent confirmation, under a right-censoring rule.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">784</enrollment>
  <condition>Muscle Invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Perioperative EV+ Pembrolizumab and RC + PLND</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 4 cycles (each cycle length = 21 days) of EV intravenous (IV) infusion plus pembrolizumab IV infusion preoperatively, followed by RC + PLND, followed by 5 cycles of adjuvant EV IV infusion plus 13 cycles of adjuvant pembrolizumab IV infusion postoperatively. The total treatment duration is up to approximately 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Neoadjuvant chemotherapy (gemcitabine + cisplatin) and RC + PLND</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 4 cycles (each cycle length = 21 days) of standard of care (SOC) chemotherapy (gemcitabine IV infusion plus cisplatin IV infusion) preoperatively, followed by RC + PLND. The total treatment duration is up to approximately 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>200 mg of Pembrolizumab IV infusion, on Day 1 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 Q3W for 13 cycles in postoperative phase (up to approximately 9 months). The total duration of treatment is up to approximately 1 year.</description>
    <arm_group_label>Arm A: Perioperative EV+ Pembrolizumab and RC + PLND</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Enfortumab vedotin (EV)</intervention_name>
    <description>1.25 mg/kg of EV IV infusion, on Day 1 and Day 8 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 and Day 8 Q3W for 5 cycles (each cycle length = 21 days) in postoperative phase (up to approximately 4 months). The total duration of treatment is up to approximately 7 months.</description>
    <arm_group_label>Arm A: Perioperative EV+ Pembrolizumab and RC + PLND</arm_group_label>
    <other_name>Padcev</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RC + PLND</intervention_name>
    <description>Curative intent RC + PLND surgery will be administered to all participants randomized to Arm A and B after completion of preoperative systemic treatment (RC + PLND to be done approximately at 15 weeks from randomization).</description>
    <arm_group_label>Arm A: Perioperative EV+ Pembrolizumab and RC + PLND</arm_group_label>
    <arm_group_label>Arm B: Neoadjuvant chemotherapy (gemcitabine + cisplatin) and RC + PLND</arm_group_label>
    <other_name>Surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m^2 of Gemcitabine IV infusion, Day 1 and Day 8 Q3W for 4 cycles in preoperative phase (up to approximately 3 months)</description>
    <arm_group_label>Arm B: Neoadjuvant chemotherapy (gemcitabine + cisplatin) and RC + PLND</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>70 mg/m^2 of Cisplatin IV infusion, Day 1, Q3W for 4 cycles in preoperative phase (up to approximately 3 months)</description>
    <arm_group_label>Arm B: Neoadjuvant chemotherapy (gemcitabine + cisplatin) and RC + PLND</arm_group_label>
    <other_name>Platinol®</other_name>
    <other_name>Platinol®-AQ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a histologically confirmed diagnosis of urothelial carcinoma (UC) / muscle&#xD;
             invasive bladder cancer (MIBC) (T2-T4aN0M0 or T1-T4aN1M0) with predominant (≥50%)&#xD;
             urothelial histology&#xD;
&#xD;
          -  Have clinically non-metastatic bladder cancer (N≤1 M0) determined by imaging (computed&#xD;
             tomography (CT) or magnetic resonance imaging (MRI) of the chest/abdomen/pelvis&#xD;
&#xD;
          -  Be deemed eligible for Radical Cystectomy (RC) + Pelvic Lymph Node Dissection (PLND)&#xD;
&#xD;
          -  Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Have adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or has required active&#xD;
             anti-cancer treatment ≤3 years of study randomization with certain exceptions&#xD;
&#xD;
          -  Has received any prior systemic treatment for MIBC or non-invasive muscle bladder&#xD;
             cancer (NMIBC - prior treatment for NMIBC with intravesical BCG/chemotherapy is&#xD;
             permitted) or prior therapy with an anti- programmed cell death 1 (PD-1),&#xD;
             anti-programmed cell death ligand 1/ ligand 2 (PD-L1/L2), or anti-cytotoxic&#xD;
             T-lymphocyte-associated protein 4 (CTLA-4)&#xD;
&#xD;
          -  Has ≥N2 disease or metastatic disease (M1) as identified by imaging&#xD;
&#xD;
          -  Is cisplatin-ineligible, as defined by meeting any one of the cisplatin ineligibility&#xD;
             criteria as per protocol&#xD;
&#xD;
          -  Has received prior systemic anticancer therapy including investigational agents within&#xD;
             3 years of randomization or any radiotherapy to the bladder&#xD;
&#xD;
          -  Has undergone partial cystectomy of the bladder to remove any NMIBC or MIBC&#xD;
&#xD;
          -  Has received a live or live attenuated vaccine within 30 days before the first dose of&#xD;
             study intervention&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or has a known history of human immunodeficiency&#xD;
             virus (HIV) infection. Hepatitis B infection or known active Hepatitis C infection&#xD;
&#xD;
          -  Has a known psychiatric or substance abuse disorder&#xD;
&#xD;
          -  Has had an allogenic tissue/solid organ transplant&#xD;
&#xD;
          -  Has ongoing sensory or motor neuropathy Grade 2 or higher&#xD;
&#xD;
          -  Has active keratitis (superficial punctate keratitis) or corneal ulcerations&#xD;
&#xD;
          -  Has a history of uncontrolled diabetes defined as hemoglobin A1c (HbA1c) ≥8% or HbA1c&#xD;
             7% to &lt;8% with associated diabetes symptoms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Joseph Heritage Healthcare-Oncology ( Site 0035)</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>714-446-5177</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-451-8751</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UF Health ( Site 0031)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>352-265-0725</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Louisville, James Graham Brown Cancer Center ( Site 0022)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>502-562-3429</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai ( Site 0011)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-659-5452</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>White Plains Hospital ( Site 0039)</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>914-849-7630</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health ( Site 0014)</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>336-713-5440</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MidLantic Urology ( Site 0002)</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>999-999-9999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Francis Cancer Center ( Site 0008)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>863-603-6300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Tennessee Medical Center ( Site 0034)</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>865-305-8780</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center ( Site 0003)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>999-999-9999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Urology Associates ( Site 0033)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>346-238-6123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urology of San Antonio ( Site 0020)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>210-614-4116</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics ( Site 0037)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>800-622-8922</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mater Hospital Brisbane ( Site 1257)</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61 7 31636166</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyell McEwin Hospital ( Site 1252)</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61882820833</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moncton Hospital ( Site 0107)</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>506-857-5669</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute ( Site 0109)</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>613-737-7700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv. Anny v Brne ( Site 0253)</name>
      <address>
        <city>Brno</city>
        <state>Brno-mesto</state>
        <zip>65691</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420543183073</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Olomouc ( Site 0251)</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420588444288</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni Thomayerova nemocnice ( Site 0252)</name>
      <address>
        <city>Praha 4</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00420261083530</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Brest -Site Hopital Morvan ( Site 0461)</name>
      <address>
        <city>Brest</city>
        <state>Finistere</state>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33298223395</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse - Oncopole ( Site 0455)</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33531155993</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Limoges Hopital Dupuytren ( Site 0459)</name>
      <address>
        <city>Limoges</city>
        <state>Haute-Vienne</state>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33555056396</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional du Orleans ( Site 0463)</name>
      <address>
        <city>Orleans</city>
        <state>Loiret</state>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33238514444</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique du Bois ( Site 0458)</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33 320009757</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Diaconesses Croix Saint Simon ( Site 0465)</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33144742839</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caritas Krankenhaus St. Josef ( Site 0502)</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+499417820</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kath. Krankenhaus Marienhospital. Universitaetsklinik ( Site 0511)</name>
      <address>
        <city>Herne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4923234991660</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Muenster ( Site 0516)</name>
      <address>
        <city>Muenster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>492518348001</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha Maria Halle-Doelau ( Site 0507)</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493455591449</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus ( Site 0509)</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00493514582157</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Alexandra&quot; ( Site 0303)</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>115 28</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00306946462998</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 0301)</name>
      <address>
        <city>Chaidari</city>
        <state>Attiki</state>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+302105831255</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larissa ( Site 0302)</name>
      <address>
        <city>Larissa</city>
        <state>Thessalia</state>
        <zip>411 10</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+00302413502124</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus-Oncology ( Site 0751)</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972-4-7776400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center-Oncology ( Site 0752)</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>97239378074</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center-ONCOLOGY ( Site 0753)</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972-3-5302191</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Santa Maria delle Grazie ( Site 0599)</name>
      <address>
        <city>Pozzuoli</city>
        <state>Napoli</state>
        <zip>80078</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>335 444645</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU San Luigi Gonzaga di Orbassano ( Site 0595)</name>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390119026993</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto IRCCS-Oncologia Medica 1 ( Site 0600)</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390498215908</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento ( Site 0598)</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>1932</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>390458122768</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Umberto I GM Lancis G Salesi ( Site 0593)</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390715964169</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele ( Site 0596)</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390226435789</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gifu University Hospital ( Site 1513)</name>
      <address>
        <city>Gifu</city>
        <state>Aichi</state>
        <zip>501-1194</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-58-230-6000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital ( Site 1512)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-52-741-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hirosaki University Hospital ( Site 1501)</name>
      <address>
        <city>Hirosaki</city>
        <state>Aomori</state>
        <zip>036-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-172-33-5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital ( Site 1502)</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-29-853-3900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanazawa University Hospital ( Site 1509)</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-76-265-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Medical Center ( Site 1508)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-45-261-5656</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center ( Site 1507)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-45-520-2222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital ( Site 1503)</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-22-717-7000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamamatsu University Hospital ( Site 1511)</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-53-435-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital ( Site 1517)</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-95-819-7200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital ( Site 1516)</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-86-223-7151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute ( Site 1514)</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-6-6945-1181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital ( Site 1515)</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-6-6645-2121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical and Dental University Hospital ( Site 1505)</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3813-6111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital ( Site 1504)</name>
      <address>
        <city>Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3353-1211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toyama University Hospital ( Site 1510)</name>
      <address>
        <city>Toyama</city>
        <zip>930-0194</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-76-434-2281</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital ( Site 1353)</name>
      <address>
        <city>Jeollanam-do</city>
        <state>Jeonranamdo</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82613797745</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital ( Site 1355)</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Kyonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82317877351</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 1352)</name>
      <address>
        <city>Songpagu</city>
        <state>Seoul</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82230103980</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Chilgok Hospital ( Site 1354)</name>
      <address>
        <city>Daegu</city>
        <state>Taegu-Kwangyokshi</state>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82532002672</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center ( Site 1356)</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82324603231</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 1351)</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82220720361</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre ( Site 0352)</name>
      <address>
        <city>Lembah Pantai</city>
        <state>Kuala Lumpur</state>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+60379492120</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarawak General Hospital ( Site 0351)</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6082-276666 ext. 6030</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii ( Site 1051)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48225462331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1053)</name>
      <address>
        <city>Przemysl</city>
        <state>Podkarpackie</state>
        <zip>37-700</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48 16 677 55 11</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewodzki im. Mikolaja Kopernika ( Site 1055)</name>
      <address>
        <city>Koszalin</city>
        <state>Zachodniopomorskie</state>
        <zip>75-581</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48502204953</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHLO, EPE - Hospital de Sao Francisco Xavier ( Site 0401)</name>
      <address>
        <city>Lisboa</city>
        <zip>1449-005</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351210431704</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Altay Regional Oncology Dispensary ( Site 0851)</name>
      <address>
        <city>Barnaul</city>
        <state>Altayskiy Kray</state>
        <zip>656045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+73852507399</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical Research Radiology Centre ( Site 0869)</name>
      <address>
        <city>Obninsk</city>
        <state>Kaluzskaja Oblast</state>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+7484399330</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Medical Research Centre of Oncology named after N.N. Blokhin ( Site 0865)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>115230</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79169982318</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Moscow State Medical University n.a. I.M.Sechenov ( Site 0871)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74955177926</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.Petersburg Clinical Hospital RAS ( Site 0864)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78122933300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Medical Univ. n.a. acad. I.P.Pavlov ( Site 0856)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>8(812) 338 60 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 0852)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>78125968947</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Oncology Hospital ( Site 0867)</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovskaya Oblast</state>
        <zip>620036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79022715868</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sverdlovsky Regional Clinical hospital #1 ( Site 0868)</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovskaya Oblast</state>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+73433511573</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Volgograd Regional Uronephrological Center ( Site 0870)</name>
      <address>
        <city>Volzhsky</city>
        <state>Volgogradskaya Oblast</state>
        <zip>404120</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78443274477</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Steve Biko Academic Hospital ( Site 0601)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27123466701</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias ( Site 0654)</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias, Principado De</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34985106121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol. ICO de Badalona ( Site 0658)</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934651200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xarxa Assistencial Universitaria Manresa ( Site 0655)</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34938759300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Doctor Josep Trueta ( Site 0653)</name>
      <address>
        <city>Girona</city>
        <state>Cataluna</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34972225832</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 0660)</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34981950511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular de Gran Canaria ( Site 0657)</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas</state>
        <zip>35001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34961452191</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0661)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934894350</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario San Carlos de Madrid ( Site 0651)</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913303000 x7554</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio ( Site 0659)</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34955012000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>I.I. Mechnykov Dnipropetrovsk Regional Clinical Hospital ( Site 0959)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380567135115</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI Clinical oncology dispensary of Dnipropetrovsk regional council ( Site 0954)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49055</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>380567209700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Center of Urology and Nephrology n.a. V.I. Shapoval ( Site 0952)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>380577387155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MNPE Regional Center of Oncology ( Site 0955)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380573151591</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise of Kharkiv Regional Council RCSDRPP ( Site 0965)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61166</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>380577003209</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lviv Oncology Regional Treatment and Diagnostic Center ( Site 0960)</name>
      <address>
        <city>Lviv</city>
        <state>Lvivska Oblast</state>
        <zip>79031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380322234440</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhytomyr Regional Oncology Center ( Site 0961)</name>
      <address>
        <city>Zhytomyr</city>
        <state>Zhytomyrska Oblast</state>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380675885098</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed cell death 1 (PD-1)</keyword>
  <keyword>Programmed Death-Ligand 1 (PD-L1)</keyword>
  <keyword>Programmed Death-Ligand 2 (PD-L2)</keyword>
  <keyword>Pelvic Lymph Node Dissection (PLND)</keyword>
  <keyword>Radical Cystectomy (RC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

